<DOC>
	<DOC>NCT02804100</DOC>
	<brief_summary>A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.</brief_summary>
	<brief_title>Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bronchial Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Bronchogenic</mesh_term>
	<criteria>Provision of informed consent Histologically confirmed stage IIIB/IV NSCLC. Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) Able to comply with the required protocol and followedup procedures, and able to receive oral medications Histologically confirmed small cell lung cancer or other metastatic tumors Patient had received prior chemotherapy or EGFRTKIs treatment Patients who harbor Exon20 T790M mutation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Circulating Tumor DNA</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Plasma DNA</keyword>
</DOC>